Diffuse large B cell lymphoma (DLBCL) affects more commonly patients over 60 years. These patients have vast number of comorbidities which can modify survival as well as other clinical parameters. The aim of this study was to evaluate prognostic significance of the National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI), absolute lymphocyte count (ALC), absolute monocyte count (AMC), lymphocyte-to-monocyte ratio (LMR) and comorbidities expressed with Charlson Comorbidity Index (CCI).
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma with the majority of patients/individuals older than 60 years [1] . Older age represents an adverse prognostic factor with poorer outcome in DLBCL patients older than 70 years (34%) comparing to patients aged 60-69 years (51%) [2] . The incidence of DLBCL in elderly patients is progressively rising [3] . The addition of rituximab to standard chemotherapy has significantly extended survival of patients with DLBCL [4, 5] . However, the treatment of elderly patients requires consideration of additional factors such as potential functional decline with age (reduction of glomerular filtration rate, reduced muscle mass, decreased liver clearance, reduced hematological reserve), comorbidities and performance status (PS) [6, 7] . Due to the age-bias, elderly patients are mostly not selected to enter clinical studies because of higher incidence of deaths not related to lymphoma [3] . The complete remission (CR) rates are lower in the elderly patients, and one of the reasons may be suboptimal treatment [3] . However, a number of factors are associated with treatment and make treatment decision more complicated.
In order to stratify risk categories, the International Prognostic Index (IPI) has been used during the past two decades [7] . However, the value of the IPI has been reported to decline in the rituximab era and revised prognostic scores have been developed [7] [8] [9] . Recently, an enhanced IPI (NCCN-IPI) from the National Comprehensive Cancer Network database has been developed, based on five parameters (age, lactate dehydrogenase (LDH), sites of involvement, Ann Arbor stage, Eastern Cooperative Oncology Group (ECOG) PS) with the progression of the age and the LDH level [10] . This index better discriminate low and high-risk subgroups compared with the IPI, but need to be evaluated in different populations of patients [10] .
Recent research studies have focused on a correlation between immune microenvironment and lymphoma biology. As the result, absolute lymphocyte count (ALC), absolute monocyte count (AMC), derived from pre-treatment cell blood counts (CBC), and lymphocyte-to-monocyte ratio (LMR) were tested. These surrogate biomarkers of the immune microenvironment, showed to be the efficient prognostic parameters in DLBCL patients treated with R-CHOP therapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) [11] [12] [13] [14] [15] . However, none of these studies have focused on the elderly population.
Comorbidities, the life-shortening diseases that were present at the time of the malignant disorder diagnosis, can be categorized using different Comorbidity scales [16] [17] [18] . Charlson Comorbidity Index (CCI) was developed by Mary Charlson in 1987 and since then has been widely used for calculating comorbidity score in cancer patients. More than 70% of the patients with aggressive NHL older than 60 years have at least one comorbidity state at presentation including hypertension (22%), heart and vascular diseases (19%) and previously diagnosed malignancies (15%) [3, 19] . The recent studies which have investigated the influence of comorbidities on the outcome of DLBCL patients, have suggested that DLBCL patients with high CCI have lower overall response rate, higher therapy related toxicity and an increased rate of lethal outcome [3, [16] [17] [18] .
This study aimed to investigate the impact of the AMC, ALC, LMR, NCCN-IPI and comorbidities on the overall survival of patients who were at the time of diagnosis 60 years and older and were treated with rituximab plus CHOP based combinations.
Patients and methods
We have retrospectively analyzed data from a total of 182 DLBCL patients who were 60 years and older, diagnosed and treated between January 2005 and December 2013 at our Institution [20] 
Statistical analyzes
Using the approach of Kaplan and Meier, overall survival (OS) and event-free survival (EFS) were analyzed [21] . Differences between survival curves were tested using the two-tailed Log Rank test. OS was calculated as the time of diagnosis the EFS and OS in univariate analysis [23] . All statistical tests were two-sided, with p value≤0.05 regarded as significant. All statistical analyses were performed in SPSS program version 21 software (IBM SPSS).
Results
A total of 182 patients (72 males/110 females) had the median age at diagnosis 68.4 years (range of 60-80 years). At diagnosis median ALC was 1.54x10 9 /L (range 0.116-14.820x10 9 /L), AMC 0.49x10 9 /L (range 0.058-8.58x10 9 /L) and LMR 3.2 (range 0.270-20.670). The ROC curves were used in order to select the cutoff points of ALC, AMC, and LMR for survival outcomes. The most discriminative cut off value for ALC was 1.10x10 9 /L, with an area under the curve (AUC) value of 0.594 (95% CI, 0.509-0.680, p=0.036) (Figure 1) . ALC>1.1x10 9 /L had 128 patients (70.3%). The most discriminative cutoff value for AMC was 0.59x10 9 /L, with an AUC value of 0.59 (95% CI, 0.503-0.676, p=0.046) (Figure 2) . AMC≤0.59x10 9 /L had 123 patients (67.6%). The most discriminative cut-off for LMR was 2.8, with an AUC value of 0.645 (95%CI, 0.562-0.728, p=0.001) (Figure 3 ). LMR<2.8 was registered in 109 patients (59.9%). High CCI≥2 was registered in 27 patients (14.8%).
Overall treatment response (CR and partial remission -PR) were achieved in 154 patients (84.6%) and 28 patients (15.4%) had primary resistant disease. CR was achieved in 126/154 patients (81.8%) and PR in 28 (18.2%) ( Table 2 ). The overall treatment response was achieved in 114 patients (89.1%) with ALC>1.1x10 9 /L comparing to 41 patients (75.9%) with ALC≤1.1x10 9 /L (p=0.029). CR and PR were achieved in 110 patients (89.4%) with AMC≤0.59x10 9 /L and in 45 patients (76.3%) with AMC>0.59x10 9 /L (p=0.019). until the last follow up point for alive patients (January 2015) or until lethal outcome. EFS was calculate as the time from diagnosis until the last follow up point for event (relapse) for alive patients (January 2015) or death. The treatment response was evaluated according to the previously reported response criteria [22] . In order to determine relationships between categorical variables Chi square test was used. The Receiver Operating Curve (ROC) method was used in order to determine optimal cut-off value for the ALC, AMC and LMR. The Cox's regression method was performed to examine the effect of parameters which had shown the prognostic impact on Regarding LMR, treatment response has been noticed in 98 patients (89.9%) with LMR>2. 8 The disease relapse was verified in 39/182 patients (24.9%) and primary resistant disease existed in 28 patients (15.4%). Adverse parameters including ALC≤1.1x10 9 /L, AMC>0.59x10 9 /L, LMR≤2.8, and NCCN-IPI≥4 were associated with higher relapse rate (p=0.008, p=0.036, p=0.005, p<0.0001, respectively) ( Table 2) .
There were no differences in survival according to the gender (Log Rank=0.093, p=0.76), presence of B symptoms (Log Rank=1.432, p=0.23) nor bulky disease (Log Rank=0.054, p=0.82). The Kaplan-Meier analysis showed that ALC>1.1x10 9 /L at diagnosis was associated with superior EFS (Log Rank=11.08, p=0.001) and OS (Log Rank=10.103, p=0.001) comparing to ALC≤1. Comorbidities were also an independent prognostic factor for EFS (HR 0.54, 95% CI, 0.294-0.976, p=0.041) and OS (HR 0.516, 95% CI, 0.282-0.942, p=0.031). Furthermore, the ALC was identified as the parameter with significant impact on the EFS (HR 0.559, 95% CI, 0.321-0.974, p=0.04) and OS (HR 0.525, 95% CI, 0.300-0.919, p=0.024) ( Table 3) . All examined parameters were tested equally in the whole group of patients, and in the particular group of 79 patients older than 70 years, and they retained their statistical significance for therapeutic outcome and survival (ALC p=0.001, NCCN-IPI p=0.011, CCI p=0.013). Regarding OS in the context of gender, tested parameters in Kaplan Mayer analysis were still valid in both male and female patients (ALC p=0.001, AMC p=0.003, LMR p=0.039, NCCN-IPI p=0.001, CCI p=0.006).
Comparing therapeutic effectiveness of R-CHOP (61 patients) vs. R-CVP (18 patients), there were no statistical differences in patients older than 70 years (Log Rank=2.25, p=0.133), since antracyclin free regimen was applied due to comorbid conditions.
Discussion
In the era of novel achievements in the field of molecular genetics using very advanced techniques such as gene expression profiling (GEP), whole genome sequencing and next generation sequencing analyses (mostly unavailable in majority of hospitals and their laboratories), the importance of attainable clinical parameters is sometimes neglected. We have tried, using easy clinical tools, to evaluate the impact of clinical parameters on the survival of elderly patients with DLBCL treated with immunochemotherpy.
Since the introduction of rituximab, the outcome of the patients with DLBCL has been significantly improved which was demonstrated also in the elderly population with DLBCL [4, 5, 24] . For the last two decades, the IPI was keystone for initial differentiation of risk categories in DLBCL patients. Developed in the pre-rituximab era, the IPI lost its power to discriminate four risk categories of patients in the rituximab era [8] [9] [10] . Since the value of the IPI has declined with the addition of rituximab, there have been made attempts in order to enhance the value of IPI designing new scoring algorithms. Recently, there has been developed the NCCN-IPI which is based on a similar set of parameters included in the IPI for recognition 4 risk groups but with refined categorization for age and level of LDH [10] . In order to further improve the value of NCCN-IPI in elderly population, the addition of albumin and β2 microglobulin were tested and proved to have prognostic significance [25] .
It is well known that the tumor microenvironment plays very important role in lymphomagenesis [26, 27] . Based on GEP studies it has been shown that gene expression by tumorinfiltrating lymphocytes and myeloid-derived cells can be used to predict clinical outcome [26] . These results were starting point in analyzing the prognostic significance of peripheral blood lymphocyte and monocyte counts as the biomarkers of immune microenvironment. Tadmor et al. suggested the prognostic value of AMC alone, even when adjusted for IPI [11] . Few other studies have suggested the prognostic impact of ALC, AMC and LMR on the OS of patients with DLBCL treated with rituximab plus CHOP or CHOP like regiments [11] [12] [13] [14] [15] . Prognostic significance of ALC at diagnosis of DLBCL was confirmed in few studies as well as in a meta-analysis published by Feng et al. based on six previously published studies [12] . On contrary, Plonquet et al. tested a group of younger DLBCL patients, and reported an association between circulating NK cell number and clinical outcome in DLBCL. However, they haven`t marked ALC as a parameter that influenced outcome [28] . The significance of AMC on survival of DLBCL patients was confirmed in few studies and became an important factor in developing and testing LMR. Furthermore, these studies confirmed the prognostic significance of ALC, AMC, LMR, absolute monocyte and lymphocyte prognostic score as the independent predictors of progression-free survival and OS [11] [12] [13] [14] [15] . However, all these studies were performed on the general DLBCL population neglecting some characteristics of the elderly population that modify treatment tolerance and outcome [3] . Our study confirmed the prognostic impact of ALC, AMC and LMR as individual parameters. But, when they were adjusted with other parameters (CCI and NCCN-IPI), only ALC retained its prognostic significance.
Since age has been considered as negative prognostic factor, different prognostic scores have been evaluated in the elderly population [29] [30] [31] [32] . The old population suffers from eminent number of co morbid conditions that are present at the time of diagnosis of lymphoma. More than 70% of patients over the age of 60 with the diagnosis of aggressive NHL have some comorbid condition according to the Eindhoven Cancer Registry [33] . Our study population had lower comorbidity rate which could be due to the undiagnosed comorbid conditions. The different comorbidity scales are available in order to estimate comorbid conditions [1618, 32] . Unfortunately, high comorbidity score sometimes leads to suboptimal treatment of these patients [3] . Using CCI, the impact of comorbid conditions on the PFS and OS of elderly patients with DLBCL has been evaluated. Few studies have shown significantly poorer outcome of the patients with high CCI≥2, as well as lower overall response rate and higher therapy related toxicity when treated with standard R-CHOP protocol [34] [35] [36] . The poorer outcome of these patients may also be due to the comorbidity itself or the lower threshold for treatment dose reduction [3] .
Our results confirmed that the NCCN-IPI was precise tool to stratify prognostically relevant subgroups of DLBCL patients over 60 years. Comorbidities in elderly patients are independently associated with poorer outcome and should be specifically evaluated at presentation in order of giving the most appropriate therapy. However, the multivariate analyses of our data showed the importance of ALC on the outcome of elderly patients with DLBCL.
Conclusion
In elderly patients with DLBCL, prognostic index such as NCCN-IPI proved its validity, while ALC can be exploited for risk stratification at diagnosis. Finally, poorer outcome can be expected in older patients with high CCI (≥2).
